Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

97.30EUR
14 Nov 2018
Change (% chg)

€-4.20 (-4.14%)
Prev Close
€101.50
Open
€101.10
Day's High
€101.70
Day's Low
€96.80
Volume
257,972
Avg. Vol
186,637
52-wk High
€124.90
52-wk Low
€70.55

Latest Key Developments (Source: Significant Developments)

Morphosys AG Announces Third Quarter 2018 Results
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - MorphoSys AG ::MORPHOSYS AG ANNOUNCES THIRD QUARTER 2018 RESULTS.Q3 REVENUE 55 MILLION EUR VERSUS 15 MILLION EUR YEAR AGO.CASH POSITION OF EUR 481.2 MILLION AS OF SEPTEMBER 30, 2018.CONFIRMS ITS 2018 FINANCIAL GUIDANCE WHICH HAD BEEN INCREASED AFTER SIGNING AN AGREEMENT WITH NOVARTIS FOR MOR106 IN JULY 2018.MORPHOSYS EXPECTS REVENUES ON UPPER END OF GUIDED RANGE FROM EUR 67 MILLION TO EUR 72 MILLION FOR 2018.  Full Article

Morphosys And Galapagos Announce U.S. Antitrust Clearance For Global License Agreement For Mor106 With Pharma Partner
Thursday, 13 Sep 2018 

Sept 12 (Reuters) - :MORPHOSYS AND GALAPAGOS ANNOUNCE U.S. ANTITRUST CLEARANCE FOR GLOBAL LICENSE AGREEMENT FOR MOR106 WITH PHARMA PARTNER.MORPHOSYS AG-FOLLOWING U.S. ANTITRUST CLEARANCE, MORPHOSYS CONFIRMS INCREASE OF ITS FINANCIAL GUIDANCE AS ALREADY COMMUNICATED ON JULY 19, 2018.  Full Article

Morphosys AG Announces Appointment Of Jennifer Herron As President Of Morphosys Us Inc
Wednesday, 25 Jul 2018 

July 24 (Reuters) - MorphoSys AG ::ANNOUNCES APPOINTMENT OF JENNIFER HERRON AS PRESIDENT OF MORPHOSYS US INC. AND EXECUTIVE VICE PRESIDENT, GLOBAL COMMERCIAL.HERRON WAS ALSO APPOINTED AS MEMBER OF THE BOARD OF DIRECTORS OF MORPHOSYS US INC.  Full Article

Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
Monday, 9 Apr 2018 

April 9 (Reuters) - MorphoSys AG ::MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING .MORPHOSYS AG SAYS OFFERING 8.3 MILLION ADSS, ASSUMING PUBLIC OFFERING PRICE OF $24.12 PER ADS.  Full Article

Morphosys Says Tremfya Approved To Treat Psoriasis In Japan
Friday, 6 Apr 2018 

April 6 (Reuters) - MorphoSys AG ::SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN.  Full Article

Morphosys AG Files For U.S. IPO Of Up To $150 Mln
Friday, 23 Mar 2018 

March 22 (Reuters) - Morphosys AG::MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING.SAYS IT INTENDS TO APPLY TO HAVE ITS ADS LISTED ON THE NASDAQ UNDER THE SYMBOL "MOR".SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, LEERINK PARTNERS ARE AMONG UNDERWRITERS TO IPO.SAYS BERENBERG CAPITAL MARKETS LLC, JMP SECURITIES ARE AMONG UNDERWRITERS TO IPO.SAYS PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.  Full Article

Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering​
Friday, 23 Mar 2018 

March 22 (Reuters) - Morphosys Ag ::SAYS ‍FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING​.SAYS ‍FINAL NUMBER OF ADSS TO BE OFFERED AND PRICE FOR OFFERING HAVE NOT YET BEEN DETERMINED​.  Full Article

Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Morphosys AG ::‍REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)​.‍EBIT LOSS 2017 AS EXPECTED AT EUR -67.6 MILLION (GUIDANCE EUR -66 TO -71 MILLION)‍.CONTINUES TO HAVE PRODUCTIVE DISCUSSIONS WITH FDA UNDER CURRENT BREAKTHROUGH THERAPY DESIGNATION ON PATH TO MARKET FOR MOR208.TALKS WITH FDA INCLUDE POSSIBILITY OF EXPEDITED REGULATORY SUBMISSION AND APPROVAL FOR MOR208 BASED PRIMARILY ON L-MIND STUDY​.SEES ‍2018 GROUP REVENUES IN RANGE OF EUR 20 TO 25 MILLION​.‍EXPECTS EARNINGS BEFORE INTEREST AND TAXES (EBIT) OF EUR -110 TO -120 MILLION IN 2018​.  Full Article

Morphosys And Galapagos Present Results From Phase 1 Study With Mor106
Monday, 19 Feb 2018 

Feb 19 (Reuters) - MORPHOSYS AG ::SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT.IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS.83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4.POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106.PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018.  Full Article

Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MORPHOSYS AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA.MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA.  Full Article

German stocks - Factors to watch on September 13

BERLIN, Sept 13 The following are some of the factors that may move German stocks on Thursday: